michael-vi-2-
Michael Vi / shutterstock.com
19 May 2020Americas

US govt argues Gilead’s patent claims are ‘insufficient’

The US government has urged a Delaware federal court to throw out patent infringement claims from  Gilead Sciences over HIV prevention medicines.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.

More on this story

Americas
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.

More on this story

Americas
5 March 2020   Drugmakers including Gilead Sciences must face antitrust claims related to HIV drugs, after the US District Court for the District of Florida on Monday, March 3 refused to fully throw out a class-action suit implicating the company.
Americas
21 February 2020   Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.